Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Protocol ID
ACNS1721
Disease (Sub Disease)
Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
Diagnosis Stage
New diagnosis
Location
NSW, QLD, VIC, WA, NZ
Sponsor
National Cancer Institute (NCI)
Trial Status
Open
Sites
The Children's Hospital at Westmead
John Hunter Children's Hospital
Monash Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
3 Years to 25 Years
International registry ID's
NCT03581292
Back to Registry
Study Title A Phase 2 Study of Veliparib (ABT-888 IND# 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Protocol ID ACNS1721
Disease (Sub Disease) Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
Diagnosis Stage New diagnosis
Location NSW / QLD / VIC / WA / NZ
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT03581292
Trial Status Open
Trial Open Date 31/10/2018
Sites The Children's Hospital at Westmead / John Hunter Children's Hospital / Monash Children's Hospital / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 2
Age Eligibility 3 Years to 25 Years
International registry ID's NCT03581292